The presented thesis deals with two novel vaccine technologies, which were analyzed in view of developing a vaccine against the respiratory syncytial virus (RSV). The first approach involved the use of non-human papilloma pseudovirions for the delivery of a DNA-vaccine. In an immunization study, mice were vaccinated in a heterologous prime-boost regimen, intramuscularly and intranasally applying a vaccine plasmid coding for the RSV F-protein packaged in MfPV11 and PcPV1 pseudovirions. In comparison to non-vaccinated mice, immunized mice showed a significantly decreased viral load upon challenge with infectious RSV. The second approach dealt with the development and analysis of a novel technology to produce killed vaccines. RSV was treated with low-energy electron irradiation (LEEI), and the required dose for complete inactivation was determined as 20kGy. Analysis of the remaining antigenicity after LEEI revealed that at least 70% of viral proteins were conserved during the process. The LEEI-treated RSV material was used in vaccination studies and yielded a strong immune response and protection against RSV upon challenge with infectious virus.